Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

07:30 - 08:20 50 mins
Registration and Morning Coffee
08:20 - 08:30 10 mins
Chairperson's Opening Remarks
  • Manuel Carrondo - Professor of Chemical and Biochemical Engineering, FCT-UNL Vice-President,, iBET Portugal
08:30 - 09:00 30 mins
Operating in a Disruptive Bioprocessing Landscape - Next Generation Bioprocessing
  • Ali Alloueche - Senior Director of Technology Strategy and Alliance Management, Takeda Vaccines, Switzerland
09:00 - 09:30 30 mins
An Update on Significant Technology Advances Enabling Integrated Continuous Bioprocessing
  • Peter Levison, Ph.D. - Senior Marketing Director, Downstream Processing, Pall Life Sciences

Over the past 15 years we have seen the widespread adoption of single-use technologies as a means to improve the efficiency and economics of new manufacturing processes within the Biotech sector. As part of the strategy towards further improving bioprocesses, there has been a great deal of interest and activity in Continuous Processing. By integrating single-use technologies into innovative process solutions for downstream processing, Pall Biotech is now able to offer a portfolio of products designed for end-to-end purification of biologics from the bioreactor. This presentation will demonstrate the scalability of this approach and demonstrate its utility to improve future bioprocesses.

09:30 - 10:00 30 mins
Future Process Development Strategies to Improve Process Productivity and Increase Capacity
  • Judy Chou - SVP and Head of Biotech, Bayer Pharmaceuticals
10:00 - 10:30 30 mins
Next Generation Process Development – Platforms, Plants and Products
10:30 - 11:15 45 mins
Morning Coffee and Networking
11:15 - 11:45 30 mins
From Early Stage to Late Stage Development: How to Characterise a Perfusion-based Vaccine Production Process using QbD?
  • Sarah Mercier - Scientist USP, Janssen, Pharmaceutical Companies of Johnson and Johnson

The biopharmaceutical industry is known for its long time-to-market and for requiring large resources and time investment for product development. The type of activities required at the start of a biopharmaceutical product development focus mainly on designing a suitable process for manufacturing as rapidly as possible material to be tested in pre-clinical and clinical trials. The number of development and GMP batches is at this stage typically limited. This is followed, upon success in early clinical trials, by a process optimization phase, which aims at increasing yields while reducing costs-of-good. Moving on towards late stage development, the manufacturing process needs to be characterized, meaning that its robustness to produce the desired product quality when operated within certain process ranges needs to be demonstrated. This phase is a major component of process development as it translates into generating large numbers of development batches using elaborate analytical methods and advanced statistics, in order to fully study the relations between the manufacturing process and product quality.

Janssen Vaccines has transitioned over the last 3 years from being focused on early stage process development, to being able to accommodate and run full late stage development programs. Janssen Vaccines also embraces the principles of Quality by Design (QbD) in its development programs, where science and risk-based approaches are used as a systematic way to build product and process understanding.

In this presentation, we present the implications of this transition from early to late stage development, with the case-study of the QbD-based characterization of a perfusion-based PER.C6® cell culture process for Adenovirus vaccine production.

11:45 - 12:15 30 mins
Computational fluid dynamics modeling for fermentation risk reduction during technology transfer and process understanding
  • Tracie Sprangler - Associate Principal Scientist, Engineering, Merck & Co., Inc., USA

Computational Fluid Dynamics modeling and in-depth scaling calculations have been utilized in partnership to generate data to support equipment design and facility fit during commercialization of a fermentation and primary recovery process for a vaccine candidate across multiple technical transfers. This analysis utilizing representative computer models for tank configurations, supplemented with traditional computational scaling approaches (ungassed P/V, gassed P/V, kLa, etc.), ensures full knowledge of a tank’s mixing and oxygen transfer capabilities allowing process understanding and robust manufacturing across technology transfer to multiple sites. Implementation of this approach across process steps as well as manufacturing sites allows increased knowledge prior to use in a process and/or prior to construction of a new vessel, therefore contributing to successful process transfer with reduced risks upon scale-up/scale-down and new facility introductions.

12:15 - 12:45 30 mins
Automated Determination of Viral Particle Yield, Purity, Size and Integrity in Downstream Process Development
  • Mathieu Colomb-Delsuc, Ph.D. - Senior Scientist, Electron Microscopy Technologies, Vironova

Numerous methods for virus characterization exist but transmission electron microscopy (TEM) is unmatched in providing detailed information on structure, integrity, aggregates and other contaminants. However, due to the need for considerable operator skills, special laboratory facilities and limitations in providing quantitative data it is not routinely used in process development. This case study shows how MiniTEM goes beyond these limitations to provide quantitative data automatically

12:45 - 14:00 75 mins
Lunch in the Exhibition Hall and Live Labs
14:00 - 14:30 30 mins
Process Development Strategies for Viral Vectors used in Gene Therapy
  • Franz Gerner - Senior Director Process Development, REGENXBIO Inc., USA

In recent years, Gene Therapy has shown promising results, resulting in the need for improved and scalable manufacturing processes due to increased vector and purity demands. Viral vectors present the majority of the gene transfer vehicles used and due to the need of maintaining integrity during the manufacturing process, new approaches for process and analytical technologies must be developed.

14:30 - 15:00 30 mins
Process Development of Retroviral Vectors for CAR-T Cell Therapies
  • Paulo Fernandes - Senior Scientist, Autolus

While retroviral vectors are one of the preferred choices for stable gene expression, the manufacture of these vectors is still limited in titer and quality. This presentation will focus on the process development efforts at Autolus to manufacture retroviral batches in sufficient amounts and with the right quality attributes for T-cell transduction and engineering.

15:00 - 15:30 30 mins
Bioprocessing of adenovirus: technical and economic considerations
  • Mats Lundgren - Customer Applications Director , GE Healthcare, Sweden

Vaccines based on viruses and viral vectors are becoming increasingly important for prevention and, more recently, for treatment of a large number of diseases. Furthermore, viral vectors such as adenovirus (AdV), adeno-associated virus (AAV), and lentivirus (LV) are also being used in gene and cell therapy.

As competition and cost pressure in the global biopharmaceutical and vaccine industry increase, the choice of manufacturing technology is gaining importance. The manufacturing processes and technologies are critical to enable cost-efficient and scalable production of safe and efficacious clinical-grade virus products.

This presentation will focus on manufacturing of AdV. We have combined experimental work and process economy calculations, from AdV production in cell culture to purified bulk product. An efficient and scalable process for AdV production was developed by evaluation of each process step. First, HEK293 suspension cells were adapted and evaluated in different serum-free cell culture media. Cell culture conditions were optimized for AdV production and tested in different single-use cell culture bioreactor systems. Filters and conditions for clarification as well as concentration and buffer exchange by tangential flow filtration were optimized. Alternatives for the downstream capture step were compared, including both chromatography resin and membrane formats. Finally, core bead technology was evaluated as an alternative to size exclusion chromatography for the polishing step before final formulation. For downstream purification, different process alternatives were compared regarding virus load capacity, recovery, and purity.  Based on analytical data, we propose a robust and scalable process with a favorable process economy.

15:30 - 16:00 30 mins
Afternoon Coffee Break
16:00 - 16:30 30 mins
Development of Vaxwave® and TheraT® viral vectors for active immunization against infectious diseases and cancer
  • Anders Lilja - VP Technical Development, Hookipa Biotech, Austria
16:30 - 17:00 30 mins
Adenovirus vector-based expression of antigens towards vaccine development
  • Santosh K Nanda - Interdisciplinary Scientist, FDA/CBER, USA (awaiting final confirmation)
17:00 - 17:10 10 mins
Plenary Changeover
17:10 - 17:40 30 mins
Scalable platform for reducing time to market of Intensified and Continuous Upstream Processes.
  • Gerben Zijlstra - Platform Manager, Sartorius

Despite their low costs, rapid deployment and flexibility, the current Single Use facilities are limited by their output, typically 500 kg/year for a 6 x 2000 L facility at 3 g/L Fed Batch titer. This also limits their usefulness for commercial scale manufacturing of multiple midsize portfolio products. Upstream process intensification can solve this limitation. With consistent effective titers of 10 g/L and beyond, annual outputs of 1500 kg/year can be realized from Single Use facilities so they become an even more attractive option for commercial manufacturing of multiple products.

To this point however the development and scale-up of intensified upstream has been cumbersome and time consuming. In this presentation a platform of upstream process intensification tools and technologies are shown, that can greatly speed-up and improve process development, scale-up and commercial scale process control.

Examples will be shown including an effective titer boost from 3 to 10 g/L in 12 days of culture, using commercially available platform tools, including cell line, media, process development tools and commercial scale manufacturing tools.

17:40 - 19:40 120 mins
End of Conference Day One and Evening Entertainment